Fenoterol

An adrenergic beta-2 agonist bronchodilatator.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Fenoterol on PubChem

BEROTEC

Link	Tested on	Impact factor	Notes	Publication date
Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2 Spike protein ACE2 Small molecule In silico	in silico	2.08	Predicted to inhibit the interaction between the SARS-CoV-2 spike protein domain S1 and the host ACE2 receptor.	Aug/21/2020
Fenoterol and dobutamine as SARS-CoV-2 main protease inhibitors: A virtual screening study 3CLpro Small molecule In silico	in silico	2.46	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Oct/13/2020
Molecular mechanism of inhibition of COVID-19 main protease by β-adrenoceptor agonists and adenosine deaminase inhibitors using in silico methods 3CLpro Small molecule In silico	in silico	3.22	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Jan/05/2021
Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods RdRpol Small molecule In silico	in silico	2.00	Predicted to inhibit SARS-CoV-2 RNA-dependent RNA polymerase.	Feb/20/2021

Link	Publication date
Quantitative structure-activity relationships, molecular docking and molecular dynamics simulations reveal drug repurposing candidates as potent SARS-CoV-2 main protease inhibitors.	Jan/19/2022
Fenoterol and dobutamine as COVID-19 main protease inhibitors: A virtual screening study	Oct/13/2020
Hemi-Babim and Fenoterol as Potential Inhibitors of MPro and Papain-like Protease against SARS-CoV-2: An In-Silico Study	Apr/05/2022
Molecular mechanism of inhibition of COVID-19 main protease by beta-adrenoceptor agonists and adenosine deaminase inhibitors using in silico methods	Jul/06/2020